Olivia Vizier

Biotech Clene Nanomedicine has gone public with a mission to use nanotherapeutics that will use gold to treat devastating neurological diseasesincluding Parkinson’s disease.

With crossover investors lining up to participate, biotechs Immuneering and Terns each raised…

Before any biologic drug enters into the clinic, it is essential to have a clear understanding of what exactly the biomolecule entails, according to Vu Truong, CEO of Aridis Pharmaceuticals. That includes both structural and physicochemical characteristics.

OncoSec’s vaccine, CORVax12, being developed in partnership with Providence Cancer Center in Portland, uses a DNA-encodable stabilized trimeric SARS-CoV-2 spike glycoprotein developed in the National Institute of Allergy and Infectious Diseases (NIAID) laboratories similar to the one used in the newly approved Moderna vaccine. It is being created with a proprietary mixture consisting of Interleukin

August was also Healthy Aging Month and, to get some perspective on the topic, we spoke to Stanford’s Dr Thomas Rando, best known for his research demonstrating that factors in young serum can directly reverse many aspects of cellular and tissue aging.

Peptidream Inc. inked a research collaboration with Amolyt Pharma SAS to test and optimize Peptidream’s growth hormone receptor antagonist (GHRA) peptides, with the aim of selecting a candidate to develop as a potential treatment for acromegaly.

X4 Pharma is a company focused on delivering innovative treatments for patients with rare diseases of the immune system. With the COVID pandemic afflicting patients around the world, those with a compromised immune system were at even greater risk.

Buffalo-formed biopharmaceutical company Athenex just got FDA approval for a topical ointment to treat it, called Klisyri.

A little over a month after a full company rebrand, the Biotech Formerly Known as Axovant has its first data readout under its new moniker.

Scientists at Recce design these antibiotics to attach to proteins in the plasma membrane of pathogens via hydrophobic interactions, which trigger cell lysis. “The bacteria can mutate as much as it likes, and the compound will still attach to the cell wall,” Graham says.

At a macro level across the globe, there is an increasing cadence, on an exponential curve, in the ability to translate basic insights into therapeutics. While the U.S. is still the world leader, other countries are making tremendous strides. The U.S. moving toward a more nationalistic framework has encouraged other countries, namely China, to own

GigaGen Inc.’s co-founder and Chief Executive Officer, explained that for decades scientists working with emerging pathogens had been concerned about the possibility of a pandemic, especially since funding decisions seemed more focused on the disease in question than the possible advantages a developing technology could provide. While many researchers may have redirected their work towards

One such company is Vaxart, based in South San Francisco, which is currently in Phase 1 human trials for a COVID-19 vaccine that’s taken as a pill.

Next year could be pivotal for Aridis. It anticipates inflection points for three immunotherapy programs and is making available for licensing its rapid mAb development technology platform, which identifies rare, potent, antibody-producing B cells for therapeutic development.

Rocket Pharmaceuticals (RCKT) announced positive Phase 1 test results for a gene therapy in heart disease — prompting RCKT stock to surge Wednesday.

Abpro Corp., a biotechnology company developing next generation antibody therapies for severe disease, is targeting a more robust antibody response with its therapeutic, ABP 300, which is based on neutralizing monoclonal antibodies.

While an adverse event in the high-dose cohort continues to outline the limits oh high volume AAV dosing…

About a year ago, Life Science Leader Chief Editor Rob Wright posed questions to several biopharma leaders for a column in the 2019 iteration of this annual Outlook issue. At least two of those questions, had they been asked just a month or so later, would have surely yielded very different responses than they did in December

Enter GigaGen’s Surge platform, which uses single-cell sequencing to “capture and recreate” libraries of antibodies from blood donors.

Last week, privately-owned Cerevance released data from a Phase Ib biomarker study of its oral compound, CVN058, evaluating the potential of the medication as a treatment for cognitive impairment associated with schizophrenia (CIAS).

“RNA interference is often better than antibodies because of the catalytic process that you can generally use,” said Chris Anzalone, CEO of Arrowhead Pharmaceuticals. A drug like inclisiran can cut LDL cholesterol in half with only two injections per year, whereas Praluent and Repatha injections are given every 2 to 4 weeks.

Invasive fungal infections are becoming increasingly common and often pose a serious public health threat, claiming the lives of more than 1.5 million people worldwide each year.

Clene Nanomedicine is trying to set a new “gold standard” in neurodegenerative diseases through the development of a new class of drugs called bioenergetic nanotherapeutics that harnesses the properties of gold nanocrystals.

“We are fortunate to collaborate with CalciMedica, a pharmaceutical company who specializes in developing drugs suppressing calcium overload in the immune cells,” Tvrdik said. “We share the vison that our research might help to identify an effective drug that will improve the recovery of stroke survivors.”

Vaxart, a San Francisco-based biotechnology company, is testing a tablet-form Covid-19 vaccine to tackle storage temperature problems, which affect even rich countries like the US, said founder Sean Tucker. “If it turns out that we will need to vaccinate people every year, it’s going to be a real challenge,” he added. “A tablet vaccine like

Clene Nanomedicine is a clinical-stage biopharmaceutical company focused on treating neurodegenerative diseases. Its chief asset is CNM-Au8, a bioenergetic nanocatalyst under development as an add-on treatment for neurodegenerative diseases like Parkinson’s disease, multiple sclerosis, and Amyotrophic Lateral Sclerosis. CNM-Au8 is part of a new class of drugs called bioenergetic nanotherapeutics that harnesses the properties of